Since mutant KRAS has been shown to interact with NFκB-activating kinases promoting cancer cell survival and drug resistance [66], it is important to examine the potential role of mutant KRAS in regulating the levels and/or ratio of proBDNF/mBDNF. The gene discussed is BDNF; the disease is cancer.